Malignant spinal cord compression (MSCC) affects 5-10% of cancer patients, primarily older individuals, with common causes including lung, prostate, breast cancers, and up to 20% of patients lacking a cancer history. Symptoms include back pain, motor/sensory deficits, and autonomic dysfunction, diagnosed primarily through MRI, with treatment focused on pain control, corticosteroids, and possible surgical intervention. Prognosis is generally poor, with a median survival of 6 months, highlighting the urgency of addressing symptoms and providing appropriate treatment swiftly.